In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous administration of mRNA-based COVID-19 and cellular quadrivalent inactivated influenza vaccines was conducted. While SARS-CoV-2 antibodies remains comparable, influenza antibody titers and seroconversion were significantly higher upon simultaneous vaccination. Magnitude of anti-influenza humoral response closely correlated with an early innate immune signature, previously described for the COVID-19 vaccine, composed of IL-15, IL-6, TNF-alpha, IFN-gamma, CXCL-10 and here extended also to acute-phase protein Pentraxin 3. People with T2D receiving simultaneous vaccination showed a protective response comparable to HS correlating with the early induction of IFN-gamma/CXCL10 and a significant reduction of the circulating glucose level due to increased oxidation of glucose digestion and consumption. These data, although preliminary and in-need of validation in larger cohorts, might be exploited to optimize future vaccination in people with chronic disorders, including diabetes.

Severa, M., Ricci, D., Etna, M. P., Facchini, M., Puzelli, S., Fedele, G., Iorio, E., Cairo, G., Castrechini, S., Ungari, V., Iannetta, M., Leone, P., Chirico, M., Pisanu, M. E., Bottazzi, B., Benedetti, L., Sali, M., Bartolomucci, R., Balducci, S., Garlanda, C., Stefanelli, P., Spadea, A., Palamara, A. T., Coccia, E. M., A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination, <<VACCINES>>, 2024; 12 (9): N/A-N/A. [doi:10.3390/vaccines12091050] [https://hdl.handle.net/10807/297103]

A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination

Ricci, Daniela;Sali, Michela;Balducci, Stefano;Stefanelli, Paola;
2024

Abstract

In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous administration of mRNA-based COVID-19 and cellular quadrivalent inactivated influenza vaccines was conducted. While SARS-CoV-2 antibodies remains comparable, influenza antibody titers and seroconversion were significantly higher upon simultaneous vaccination. Magnitude of anti-influenza humoral response closely correlated with an early innate immune signature, previously described for the COVID-19 vaccine, composed of IL-15, IL-6, TNF-alpha, IFN-gamma, CXCL-10 and here extended also to acute-phase protein Pentraxin 3. People with T2D receiving simultaneous vaccination showed a protective response comparable to HS correlating with the early induction of IFN-gamma/CXCL10 and a significant reduction of the circulating glucose level due to increased oxidation of glucose digestion and consumption. These data, although preliminary and in-need of validation in larger cohorts, might be exploited to optimize future vaccination in people with chronic disorders, including diabetes.
2024
Inglese
Severa, M., Ricci, D., Etna, M. P., Facchini, M., Puzelli, S., Fedele, G., Iorio, E., Cairo, G., Castrechini, S., Ungari, V., Iannetta, M., Leone, P., Chirico, M., Pisanu, M. E., Bottazzi, B., Benedetti, L., Sali, M., Bartolomucci, R., Balducci, S., Garlanda, C., Stefanelli, P., Spadea, A., Palamara, A. T., Coccia, E. M., A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination, <<VACCINES>>, 2024; 12 (9): N/A-N/A. [doi:10.3390/vaccines12091050] [https://hdl.handle.net/10807/297103]
File in questo prodotto:
File Dimensione Formato  
vaccines-12-01050-v2.pdf

accesso aperto

Licenza: Creative commons
Dimensione 4.87 MB
Formato Adobe PDF
4.87 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/297103
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact